Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
about
Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence.A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment OutcomeTegumentary leishmaniasis in the State of Amazonas: what have we learned and what do we need?Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisDynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosineMonitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesDrug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasisMiltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in ColombiaRandomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in SurinameDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Ecological aspects and molecular detection of Leishmania DNA Ross (Kinetoplastida: Trypanosomatidae) in phlebotomine sandflies (Diptera: Psychodidae) in terra firme and várzea environments in the Middle Solimões Region, Amazonas State, Brazil.Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasisLow versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.Leishmaniasis: a review.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.An update on pharmacotherapy for leishmaniasisSpecies-directed therapy for leishmaniasis in returning travellers: a comprehensive guideCutaneous leishmaniasis: recent developments in diagnosis and managementNoninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in childrenLeishmaniasis in the United States: treatment in 2012Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Efficacy and safety of a single dose pentamidine (7mg/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot studyIntralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous LeishmaniasisClinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment.Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.Leishmaniasis: new insights from an old and neglected disease.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Parasitic diseases in travelers: a focus on therapy.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis.Chemotherapy of leishmaniasis: present challenges.Evaluating drug resistance in visceral leishmaniasis: the challenges.Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.American cutaneous leishmaniasis in infancy and childhood.
P2860
Q27022964-CFC3EA0F-DD92-4FF7-87A7-6184604A36C3Q27303693-69DBDED9-682C-42A2-BD8D-8BDE076C2639Q28083320-90EBE4C4-EA80-4E8A-97E8-AF26F60D904BQ28088410-6D58D91C-F8EC-44E4-A727-80EF0B6D0254Q28271849-CA7AE87A-4547-45E5-AC4F-360A629CEF6DQ28478376-F125902C-6621-4659-AB96-974AA6894502Q28480699-D34B7A05-8B92-4237-BD1A-4BCADDEC3645Q28482212-276B3104-FFC7-4748-AA78-384089E85C4EQ28483875-472B9B6B-1785-4C6B-945E-53DD96DA9475Q28539068-BAF2C46C-A1F1-4084-9336-72FA292F95C2Q28544790-5206EC79-19B0-4341-9749-0F80FE42BAD2Q30275257-2A8832C5-BAF3-4BDB-B9B4-0F3015DDFD30Q30389233-28F80197-75ED-4A6B-9C82-35DA299E62F5Q33602811-18408B5B-EEBF-4635-9C2F-EF97C0AD847BQ33739398-1CDD0340-D0E5-4991-BCDC-14BCA9CF7B13Q33777851-B8B3C140-9274-4CF0-96DB-124014B66830Q34700686-1DE194EE-22A4-4872-92BF-489B6B751E08Q34945204-B24AA53B-B4D6-4EC7-918A-90AF57180933Q35160905-595E38B1-29D9-4F24-BEB9-3AAA4C9DB00DQ35187729-A81731DE-D868-47D8-AE46-029E4A45AAE8Q35694752-5ED4D402-0DF8-4D65-9700-450248EA362EQ35771790-FB53453B-8CF4-4F10-BEB4-DCFF3B499DE1Q36086339-0BDCB758-A489-42BA-9756-694D9982EB22Q36398273-EB544922-DB19-448D-AC35-C6B0BE47E39BQ36776108-BAF820A4-F0BD-4621-93E4-782DC6BB477DQ37089640-A5AB7B26-BFB6-4B2A-8FAB-30A9597383A8Q37669845-F7AD96D0-1DFE-4225-B071-0695B4688D1FQ37712995-68395410-6100-4817-848C-5639B5A4DF9BQ37870821-79B3B3E4-D68D-4B98-8422-37E6EE632ECAQ38136837-F9DCD407-F3A6-4713-B5CF-37797D5C2818Q38156421-26471F66-BC0A-4EDC-8912-95035C1C5DD7Q38192001-25D3EE6D-92A6-4D07-B55B-07F90EE6574DQ38205451-CE30368F-82DE-452B-B2D5-4DD6E34819A3Q38263615-D12994A2-1329-4EA3-BA5E-20677FD82EF4Q38511211-A00C52DB-72FE-4DDA-8F07-E201F4C8B3B4Q38995293-137205F0-B722-4E30-8471-581ADA9B09A0Q39011875-64AA7112-5E54-4C65-B6D8-0EC942F2EC97Q39014583-36D8C188-557F-41BE-A25E-2A56F4D7CBD8Q39273435-FFD8C877-F465-4856-82B8-453142AD445CQ39336818-3FF3ADCB-0EEC-4F51-B05E-4C075E45310F
P2860
Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@ast
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@en
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@nl
type
label
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@ast
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@en
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@nl
prefLabel
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@ast
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@en
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@nl
P2093
P2860
P1476
Randomized controlled clinical ...... guyanensis in Manaus, Brazil.
@en
P2093
Anette Chrusciak-Talhari
Carolina Chrusciak Talhari
Ellen Priscila Gadelha Yamashita
Gerson de Oliveira Penna
Paulo Roberto Lima Machado
Reynaldo Dietze
Roberto Moreira da Silva
Sinésio Talhari
P2860
P304
P356
10.4269/AJTMH.2011.10-0155
P407
P577
2011-02-01T00:00:00Z